Skip to main content
SpringerLink
Log in

Neuroendocrine Neoplasms of the Lung

  • Chapter
  • First Online:
The Thorax

  • 636 Accesses

Abstract

Neuroendocrine tumors (NETs) represent a heterogeneous group of neoplasms with a morphologic spectrum that ranges from well-differentiated tumors such as typical carcinoids of the lung, intermediate-grade neoplasms like atypical carcinoids, and high-grade or poorly differentiated tumors such as small cell lung carcinoma and large-cell neuroendocrine carcinoma. These tumors comprise 25% of primary lung neoplasms and are thought to arise from specialized neuroendocrine cells that form a part of the epithelial lining of the bronchial tree. These cells, known as pulmonary neuroendocrine cells (PNECs) or Kulchitshy cells, are phylogenetically ancient and believed to be of endodermal origin. They are also found in the gastrointestinal tract. The management and prognosis of pulmonary neuroendocrine tumors vary widely. In this chapter, we will discuss the clinical, radiological, and pathological correlates of the spectrum of neuroendocrine neoplasms of the lung to provide information that can be directly applied to clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Borczuk A. Pulmonary neuroendocrine tumors. Surg Pathol Clin. 2020;13(1):35–55.

    Article  PubMed  Google Scholar 

  2. Hendifar A, Marchevsky A, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol. 2017;12(3):425–36.

    Article  PubMed  Google Scholar 

  3. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010;134(11):1628–38.

    Article  PubMed  Google Scholar 

  4. Rogers D. Phylogenetic aspects of the neuroepithelial bodies. Arch Histol Cytol. 1989;52(Suppl):397–402.

    Article  PubMed  Google Scholar 

  5. Gustafsson B, Kidd M, Chan A, Malfertheiner M, Modlin I. Bronchopulmonary neuroendocrine tumors. Cancer. 2008;113(1):5–21.

    Article  CAS  PubMed  Google Scholar 

  6. Lauweryns J, Van Lommel A, Dom R. Innervation of rabbit intrapulmonary neuroepithelial bodies. Quantitative and qualitative ultrastructural study after vagotomy. J Neurol Sci. 1985;67(1):81–92.

    Article  CAS  PubMed  Google Scholar 

  7. Van Lommel A. Pulmonary neuroendocrine cells (PNEC) and neuroepithelial bodies (NEB): chemoreceptors and regulators of lung development. Paediatr Respir Rev. 2001;2:171–6.

    PubMed  Google Scholar 

  8. Van Lommel A, Bollé T, Fannes W, Lauweryns J. The pulmonary neuroendocrine system: the past decade. Arch Histol Cytol. 1999;62(1):1–16.

    Article  PubMed  Google Scholar 

  9. Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics. 2006;26:41–57; discussion 57–8.

    Article  PubMed  Google Scholar 

  10. Filosso PL, Oliaro A, Ruffini E, et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol. 2013;8(10):1282–8.

    Article  PubMed  Google Scholar 

  11. Warren W, Gould V. Long-term follow-up of classical bronchial carcinoid tumors. Clinicopathologic observations. Scand J Thorac Cardiovasc Surg. 1990;24(2):125–30.

    Article  CAS  PubMed  Google Scholar 

  12. Aguayo S, Miller Y, Waldron J, et al. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med. 1992;327(18):1285–8.

    Article  CAS  PubMed  Google Scholar 

  13. Wirtschafter E, Walts A, Liu S, Marchevsky A. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia of the lung (DIPNECH): current best evidence. Lung. 2015;193(5):659–67.

    Article  CAS  PubMed  Google Scholar 

  14. Rossi G, Cavazza A, Spagnolo P, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. Eur Respir J. 2016;47(6):1829–41.

    Article  CAS  PubMed  Google Scholar 

  15. Carr L, Chung J, Duarte Achcar R, et al. The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Chest. 2015;147(2):415–22.

    Article  PubMed  Google Scholar 

  16. Davies S, Gosney J, Hansell D, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax. 2007;62(3):248–52.

    Article  PubMed  Google Scholar 

  17. Nassar AA, Jaroszewski DE, Helmers RA, Colby TV, Patel BM, Mookadam F. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview. Am J Respir Crit Care Med. 2011;184(1):8–16.

    Article  PubMed  Google Scholar 

  18. Degan S, Lopez GY, Kevill K, Sunday ME. Gastrin-releasing peptide, immune responses, and lung disease. Ann N Y Acad Sci. 2008;1144:136–47.

    Article  CAS  PubMed  Google Scholar 

  19. He P, Gu X, Wu Q, Lin Y, Gu Y, He J. Pulmonary carcinoid tumorlet without underlying lung disease: analysis of its relationship to fibrosis. J Thorac Dis. 2012;4(6):655–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Chauhan A, Ramirez RA. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and the role of somatostatin analogs: a case series. Lung. 2015;193(5):653–7.

    Article  CAS  PubMed  Google Scholar 

  21. Rossi G, Cavazza A, Graziano P, Papotti M. mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Am J Respir Crit Care Med. 2012;185(3):341; author reply 341–2.

    Article  PubMed  Google Scholar 

  22. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119(6):1647–51.

    Article  CAS  PubMed  Google Scholar 

  23. Naalsund A, Rostad H, Strøm E, Lund M, Strand T. Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg. 2011;39(4):565–9.

    Article  PubMed  Google Scholar 

  24. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001;12(9):1295–300.

    Article  CAS  PubMed  Google Scholar 

  25. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.

    Article  PubMed  Google Scholar 

  26. Caplin M, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European neuroendocrine tumor society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604–20.

    Article  CAS  PubMed  Google Scholar 

  27. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer. 2008;123(4):867–73.

    Article  CAS  PubMed  Google Scholar 

  28. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92(8):2204–10.

    Article  CAS  PubMed  Google Scholar 

  29. Oliveira AM, Tazelaar HD, Wentzlaff KA, et al. Familial pulmonary carcinoid tumors. Cancer. 2001;91(11):2104–9.

    Article  CAS  PubMed  Google Scholar 

  30. Davila D, Dunn W, Tazelaar H, Pairolero P. Bronchial carcinoid tumors. Mayo Clin Proc. 1993;68(8):795–803.

    Article  CAS  PubMed  Google Scholar 

  31. Marty-Ané C, Costes V, Pujol J, Alauzen M, Baldet P, Mary H. Carcinoid tumors of the lung: do atypical features require aggressive management. Ann Thorac Surg. 1995;59(1):78–83.

    Article  PubMed  Google Scholar 

  32. Harpole DH Jr, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg. 1992;54(1):50–4; discussion 54–5.

    Article  PubMed  Google Scholar 

  33. Hage R, de la Riviere AB, Seldenrijk CA, van den Bosch JM. Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol. 2003;10(6):697–704.

    Article  CAS  PubMed  Google Scholar 

  34. Thomas R, Christopher D, Balamugesh T, Shah A. Clinico-pathologic study of pulmonary carcinoid tumours--a retrospective analysis and review of literature. Respir Med. 2008;102(11):1611–4.

    Article  PubMed  Google Scholar 

  35. Gao Y, Moua T, Midthun D, Mullon J, Decker P, Ryu J. Diagnostic yield and bleeding complications associated with bronchoscopic biopsy of endobronchial carcinoid tumors. J Bronchol Interv Pulmonol. 2020;27(3):184–9.

    Article  Google Scholar 

  36. Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–34.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Melmon KL, Sjoerdsma A, Mason DT. Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumors. Am J Med. 1965;39(4):568–81.

    Article  CAS  PubMed  Google Scholar 

  38. Aniszewski JP, Young WF Jr, Thompson GB, Grant CS, van Heerden JA. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg. 2001;25(7):934–40.

    Article  CAS  PubMed  Google Scholar 

  39. Limper AH, Carpenter PC, Scheithauer B, Staats BA. The Cushing syndrome induced by bronchial carcinoid tumors. Ann Intern Med. 1992;117(3):209–14.

    Article  CAS  PubMed  Google Scholar 

  40. Fasano M, Della Corte C, Papaccio F, Ciardiello F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol. 2015;10(8):1133–41.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Filosso PL, Donati G, Rena O, Oliaro A. Acromegaly as manifestation of a bronchial carcinoid tumour. Asian Cardiovasc Thorac Ann. 2003;11(2):189.

    Article  PubMed  Google Scholar 

  42. Athanassiadi K, Exarchos D, Tsagarakis S, Bellenis I. Acromegaly caused by ectopic growth hormone-releasing hormone secretion by a carcinoid bronchial tumor: a rare entity. J Thorac Cardiovasc Surg. 2004;128(4):631–2.

    Article  PubMed  Google Scholar 

  43. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656–63.

    Article  CAS  PubMed  Google Scholar 

  44. Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(16):1556–7.

    PubMed  Google Scholar 

  45. Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol. 2001;12(10):1383–91.

    Article  CAS  PubMed  Google Scholar 

  46. Crona J, Fanola I, Lindholm DP, et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology. 2013;98(2):151–5.

    Article  CAS  PubMed  Google Scholar 

  47. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–77.

    Article  CAS  PubMed  Google Scholar 

  48. Lou F, Sarkaria I, Pietanza C, et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg. 2013;96(4):1156–62.

    Article  PubMed  Google Scholar 

  49. Ferguson MK, Landreneau RJ, Hazelrigg SR, et al. Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg. 2000;18(2):156–61.

    Article  CAS  PubMed  Google Scholar 

  50. Thomas CF Jr, Tazelaar HD, Jett JR. Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. Chest. 2001;119(4):1143–50.

    Article  PubMed  Google Scholar 

  51. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.

    Article  PubMed  Google Scholar 

  52. Surveillance, Epidemiology and End Results (SEER) Program. www.seer.cancer.gov.

  53. Xu F, Chen K, Lu C, et al. Large cell neuroendocrine carcinoma shares similarity with small cell carcinoma on the basis of clinical and pathological features. Transl Oncolgy. 2019;12(4):646–55.

    Article  Google Scholar 

  54. Kinslow CJ, May MS, Saqi A, et al. Large-cell neuroendocrine carcinoma of the lung: a population-based study. Clin Lung Cancer. 2020;21(2):e99–113.

    Article  PubMed  Google Scholar 

  55. Sakurai H, Asamura H. Large-cell neuroendocrine carcinoma of the lung. Thorac Surg Clin. 2014;24(3):305–11.

    Article  PubMed  Google Scholar 

  56. Takei H, Asamura H, Maeshima A, et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg. 2002;124(2):285–92.

    Article  PubMed  Google Scholar 

  57. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24(1):70–6.

    Article  PubMed  Google Scholar 

  58. Battafarano R, Fernandez F, Ritter J, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130(1):166–72.

    Article  PubMed  Google Scholar 

  59. Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment. J Natl Compr Cancer Netw. 2011;9(10):1122–9.

    Article  Google Scholar 

  60. Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33(5):853–61.e4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. De Pas TM, Giovannini M, Manzotti M, et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol. 2011;29(34):e819–22.

    Article  PubMed  Google Scholar 

  62. Benson RE, Rosado-de-Christenson ML, Martinez-Jimenez S, Kunin JR, Pettavel PP. Spectrum of pulmonary neuroendocrine proliferations and neoplasms. Radiographics. 2013;33:1631–49.

    Article  PubMed  Google Scholar 

  63. Mandegaran R, David S, Screaton N. Cardiothoracic manifestations of neuroendocrine tumours. Br J Radiol. 2016;89:20150787.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Koo CW, Baliff JP, Torigian DA, Litzky LA, Gefter WB, Akers SR. Spectrum of pulmonary neuroendocrine cell proliferation: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids. AJR Am J Roentgenol. 2010;195:661–8.

    Article  PubMed  Google Scholar 

  65. Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008;13:1255–69.

    Article  CAS  PubMed  Google Scholar 

  66. Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22:517–30.

    CAS  PubMed  Google Scholar 

  67. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  PubMed  Google Scholar 

  68. Jeung MY, Gasser B, Gangi A, et al. Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings. Radiographics. 2002;22:351–65.

    Article  PubMed  Google Scholar 

  69. Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2006;33:532–40.

    Article  PubMed  Google Scholar 

  70. Moore W, Freiberg E, Bishawi M, et al. FDG-PET imaging in patients with pulmonary carcinoid tumor. Clin Nucl Med. 2013;38:501–5.

    Article  PubMed  Google Scholar 

  71. Chong S, Lee KS, Kim BT, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188:1223–31.

    Article  PubMed  Google Scholar 

  72. Oshiro Y, Kusumoto M, Matsuno Y, et al. CT findings of surgically resected large cell neuroendocrine carcinoma of the lung in 38 patients. AJR Am J Roentgenol. 2004;182:87–91.

    Article  PubMed  Google Scholar 

  73. Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001;91:1992–2000.

    Article  CAS  PubMed  Google Scholar 

  74. Varlotto JM, Medford-Davis LN, Recht A, et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? J Thorac Oncol. 2011;6:1050–8.

    Article  PubMed  Google Scholar 

  75. Nocun A, Chrapko B, Golebiewska R, Stefaniak B, Czekajska-Chehab E. Evaluation of somatostatin receptors in large cell pulmonary neuroendocrine carcinoma with 99mTc-EDDA/HYNIC-TOC scintigraphy. Nucl Med Commun. 2011;32:522–9.

    Article  CAS  PubMed  Google Scholar 

  76. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001;28(2 Suppl 4):3–13.

    Article  CAS  PubMed  Google Scholar 

  77. Zhao H, Ren D, Liu H, Chen J. Comparison and discussion of the treatment guidelines for small cell lung cancer. Thorac cancer. 2018;9(7):769–74.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Elias A. Small cell lung cancer: state-of-the-art therapy in 1996. Chest. 1997;112(4 Suppl):251S–8S.

    Article  CAS  PubMed  Google Scholar 

  79. Stupp R, Monnerat C, Turrisi A, Perry M, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer. 2004;45(1):105–17.

    Article  PubMed  Google Scholar 

  80. Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi99–105.

    Article  PubMed  Google Scholar 

  81. Kalemkerian G, Schneider B. Advances in small cell lung cancer. Hematol Oncol Clin North Am. 2017;31(1):143–56.

    Article  PubMed  Google Scholar 

  82. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44.

    Article  PubMed  Google Scholar 

  83. Bade B, Dela CC. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24.

    Article  PubMed  Google Scholar 

  84. Zarogoulidis K, Porpodis K, Domvri K, Eleftheriadou E, Ioannidou D, Zarogoulidis P. Diagnosing and treating pancoast tumors. Expert Rev Respir Med. 2016;10(12):1255–8.

    Article  CAS  PubMed  Google Scholar 

  85. Seute T, Leffers P, ten Velde G, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer. 2004;100(4):801–6.

    Article  PubMed  Google Scholar 

  86. Gazdar A, Bunn P, Minna J. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17(12):725–37.

    Article  CAS  PubMed  Google Scholar 

  87. Pearlberg JL, Sandler MA, Lewis JW, Beute GH, Alpern MB. Small-cell bronchogenic carcinoma: CT evaluation. Am J Roentgenol. 1988;150(2):265–8.

    Article  CAS  Google Scholar 

  88. Ryu JS, Lim JH, Lee JM, et al. Minimal pleural effusion in small cell lung cancer: proportion, mechanisms, and prognostic effect. Radiology. 2016;278(2):593–600.

    Article  PubMed  Google Scholar 

  89. Agrawal A, Tandon R, Singh L, Chawla A. Clinico- pathological profile and course of malignant pleural effusion in a tertiary care teaching hospital in western U.P. with special reference to lung cancer. Lung India : official organ of Indian chest. Society. 2015;32(4):326–30.

    Google Scholar 

  90. Rahman NM, Ali NJ, Brown G, et al. Local anaesthetic thoracoscopy: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii54–60.

    Article  PubMed  Google Scholar 

  91. Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. 2003;58(Suppl 2):ii8–17.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Network NCC. Small cell lung cancer (version 1.2021). https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.

  93. Tendler S, Grozman V, Lewensohn R, Tsakonas G, Viktorsson K, De Petris L. Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden. Lung Cancer. 2018;120:75–81.

    Article  PubMed  Google Scholar 

  94. Shirasawa M, Fukui T, Kusuhara S, et al. Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. Cancer Manag Res. 2018;10:6039–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Shepherd FA, Crowley J, Van Houtte P, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol. 2007;2(12):1067–77.

    Article  PubMed  Google Scholar 

  96. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.

    Article  PubMed  Google Scholar 

  97. Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15(2):187–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer. 2005;6(6):355–60.

    Article  PubMed  Google Scholar 

  99. Janne PA, Freidlin B, Saxman S, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer. 2002;95(7):1528–38.

    Article  PubMed  Google Scholar 

  100. Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. J Natl Compr Cancer Netw. 2013;11(1):78–98.

    Article  CAS  Google Scholar 

  101. Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J. 2010;35(1):202–15.

    Article  CAS  PubMed  Google Scholar 

  102. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8.

    Article  CAS  PubMed  Google Scholar 

  104. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–72.

    Article  CAS  PubMed  Google Scholar 

  105. Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2(9):798–811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83.

    Article  CAS  PubMed  Google Scholar 

  107. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39.

    Article  CAS  PubMed  Google Scholar 

  108. Goetze TO. Immunotherapy: a new era in small-cell lung cancer. Lancet. 2019;394(10212):1884–5.

    Article  PubMed  Google Scholar 

  109. National Lung Screening Trial Research Team, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JRD, Jain A, Sarah Baum Collaborator. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91.

    Article  Google Scholar 

  110. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–9.

    Article  PubMed  Google Scholar 

  111. Cuffe S, Moua T, Summerfield R, Roberts H, Jett J, Shepherd FA. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol. 2011;6(4):818–22.

    Article  PubMed  Google Scholar 

  112. Yabuuchi H, Murayama S, Sakai S, et al. Resected peripheral small cell carcinoma of the lung: computed tomographic-histologic correlation. J Thorac Imaging. 1999;14:105–8.

    Article  CAS  PubMed  Google Scholar 

  113. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:1614–20.

    Article  CAS  PubMed  Google Scholar 

  114. Thomson D, Hulse P, Lorigan P, Faivre-Finn C. The role of positron emission tomography in management of small cell lung cancer. Lung Cancer. 2011;73:121–6.

    Article  CAS  PubMed  Google Scholar 

  115. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338–45.

    Article  CAS  PubMed  Google Scholar 

  116. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–75.

    Article  PubMed  Google Scholar 

  117. Huang X, Liang QL, Jiang L, et al. Primary pulmonary Paraganglioma: a case report and review of literature. Medicine (Baltimore). 2015;94:e1271.

    Article  PubMed  Google Scholar 

  118. Gan F, Xia L, Liu L. Primary pulmonary paraganglioma. QJM. 2018;111:901–2.

    Article  CAS  PubMed  Google Scholar 

  119. Kiziltan HS, Ozucer B, Eris AH, Veyseller B. Bilateral carotid paraganglioma: surgery and radiotherapy. Clin Med Insights Case Rep. 2014;7:53–7.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Shi H, Han J, Liu N, et al. A gangliocytic patially glandular paraganglioma with lymph node metastasis. Diagn Pathol. 2014;9:63.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Zhang JJ, Liu T, Peng F. Primary paraganglioma of the lung: a case report and literature review. J Int Med Res. 2012;40:1617–26.

    Article  PubMed  Google Scholar 

  122. Fiorentino G, Annunziata A, De Rosa N. Primary paraganglioma of the lung: a case report. J Med Case Rep. 2015;9:166.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Oberndorfer S. Karzinoide Tumoren des Dunndarms. Frank Z Pathol. 1907;1:425–32.

    Google Scholar 

  124. Bunting CH. Multiple primary carcinomata of the ileum. Johns Hopkins Hosp Bull. 1904;165:389–94.

    Google Scholar 

  125. Gould VE, Linnoila RI, Memoli VA, Warren WH. Neuroendocrine cells and neuroendocrine neoplasms of the lung. Pathol Annu. 1983;18:287–330.

    PubMed  Google Scholar 

  126. Paladugu RR, Benfeld JR, Pak HY, Ross RK, Teplitz RL. Bronchopulmonary kultchitzky cell carcinomas: a new classification scheme for typical and atypical carcinoids. Cancer. 1985;55:1303–11.

    Article  CAS  PubMed  Google Scholar 

  127. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas, and gut. Virchows Arch. 1994;425:547–60.

    Google Scholar 

  128. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–44.

    Article  CAS  PubMed  Google Scholar 

  129. Huang Q, Muzitansky A, Mark EJ. Pulonary neuroendocrine carcinomas: a review of 234 cases and statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification. Arch Pathol Lab Med. 2002;126:545–53.

    Article  PubMed  Google Scholar 

  130. Moran CA, Suster S, Coppola D, Wick MR. Neuroendocrine carcinomas of the lung: a critical review. Am J Surg Pathol. 2009;13:206–21.

    Google Scholar 

  131. Tsuta K, Raso MG, Kalhor N, et al. Histologic features of low-and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer. 2011;71:34–41.

    Article  PubMed  Google Scholar 

  132. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972;64:413–21.

    Article  CAS  PubMed  Google Scholar 

  133. Filosso PL, Rena O, Donati G, et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg. 2002;123:303–9.

    Article  PubMed  Google Scholar 

  134. Garcia-Yuste M, Matilla JM, Cueto A, et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish multi-centric study of neuroendocrine tumours of the lung. Eur J Cardiothorac Surg. 2007;31:192–7.

    Article  PubMed  Google Scholar 

  135. Mezzetti M, Raveglia F, Panigalli T, et al. Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification. Ann Thorac Surg. 2003;76:1838–42.

    Article  PubMed  Google Scholar 

  136. Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg. 2004;77:1781–5.

    Article  PubMed  Google Scholar 

  137. Moran CA, Lindholm KE, Brunnstrom H, et al. Typical and atypical carcinoid tumors of the lung: a clinicopathological correlation of 783 cases with emphasis on histological features. Hum Pathol. 2020;98:98–109.

    Article  PubMed  Google Scholar 

  138. Mooi WJ, Dewar A, Springall D, et al. Non-small cell lung carcinomas with neuroendocrine features. A light microscopic, immunohistochemical and ultrastructural study of 11 cases. Histopathology. 1988;13:329–37.

    Article  CAS  PubMed  Google Scholar 

  139. Dresler CM, Ritter JH, Patterson GA, et al. Clinical-pathological analysis of 40 patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 1997;63:180–5.

    Article  CAS  PubMed  Google Scholar 

  140. Yang YJ, Steele CT, Ou XL, et al. Diagnosis of high-grade pulmonary neuroendocrine carcinoma by fine needle aspiration biopsy. Cytopathology. 2001;25:292–300.

    Article  CAS  Google Scholar 

  141. Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between “small cells” and “large cells” in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol. 2001;116:466–72.

    Article  CAS  PubMed  Google Scholar 

  142. Iyoda A, Hiroshima K, Toyozaki T, et al. Clinical characgterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine features. Cancer. 2001;91:1992–2000.

    Article  CAS  PubMed  Google Scholar 

  143. Huang X, Liang QL, Jiang L, et al. Primary pulmonary paraganglioma: a case report and review of literature. Medicine. 2015;94:e1271.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Dahir KM, Gonzales A, Revelo MP, et al. Ectopic adrenocorticotropic hormone hypersecretion due to a primary pulmonary paraganglioma. Endocr Pract. 2004;10:424–8.

    Article  PubMed  Google Scholar 

  145. Aubertine CL, Flieder DB. Primary paraganlgioma of the lung. Ann Diagn Pathol. 2004;8:237–41.

    Article  PubMed  Google Scholar 

  146. Palau MA, Merino MJ, Quezado M. Corticotropin-producing pulmonary gangliocytic paraganglioma associated with Cushing’s syndrome. Hum Pathol. 2006;37:623–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Texas San Antonio, San Antonio, TX, USA

    Philip G. Ong

  2. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Chad D. Strange, Jitesh Ahuja, Girish S. Shroff, Bradley S. Sabloff, Patricia M. de Groot & Mylene T. Truong

  3. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Cesar A. Moran

Authors
  1. Philip G. Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chad D. Strange
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jitesh Ahuja
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Girish S. Shroff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bradley S. Sabloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patricia M. de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mylene T. Truong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cesar A. Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia M. de Groot .

Editor information

Editors and Affiliations

  1. Department of Pathology, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Cesar A. Moran

  2. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Mylene T. Truong

  3. Department of Thoracic Imaging, The University of Texas MD Anderson Cancer, Houston, TX, USA

    Patricia M. de Groot

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ong, P.G. et al. (2023). Neuroendocrine Neoplasms of the Lung. In: Moran, C.A., Truong, M.T., de Groot, P.M. (eds) The Thorax. Springer, Cham. https://doi.org/10.1007/978-3-031-21040-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-21040-2_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-21039-6

  • Online ISBN: 978-3-031-21040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation